Instructions for Amlodipine Aspartate Tablets
Release time:
2020-07-31
Approval Date: October 23, 2006
First Amendment Date: June 20, 2010
Second Amendment Date: May 05, 2015
Amlodipine Aspartate Tablets Instruction
Aspartic acid Amlodipine Tablets
Please read the instruction carefully and use
[Drug Name]
generic name under the guidance of a doctor: amlodipine aspartate tablets
trade name: liside
English name: Aspartic acid Amlodipine Tablets
Chinese pinyin: Men dong an suan an lu di ping plan-
[ingredients] the main ingredient of this product is L-amlodipine aspartate
chemical name: 2-1 [2-aminoethoxy] methyl] -4-1 (2-chlorophenyl) -1,4-dihydrogen -6-methyl pyridine -3,5-3-ethyl -5-methyl ester L-a-aspartic acid salt.
Chemical Structural Formula:
Molecular Formula: C20H25CIN205 C4H7N04
Molecular Weight: 541.99
[Character] This product is white or white-like sheet
[Indications] It can be used alone or in combination with other antihypertensive drugs to treat hypertension
[Specification] 5mg (based on amlodipine)
[Usage and Dosage] Usually the initial dose is 5mg (one sheet) once a day, but the elderly, frail, liver damage patients and patients with other antihypertensive drugs, the initial dose can be 2.5mg (half a tablet), once a day. Dosage adjustment should be based on the clinical response of the individual patient, the maximum dose can be increased to 10mg (two tablets), once a day. This product is combined with thiazide diuretics, beta blockers and angiotensin converting enzyme inhibitors without dose adjustment.
[Adverse Reactions] The more common adverse reactions are headache, edema, fatigue, insomnia, nausea, abdominal pain, flushing, palpitations and dizziness. Less common adverse reactions are angina, hypotension, bradycardia, orthostatic hypotension, pruritus, rash, dyspnea, weakness, muscle cramps, and dyspepsia. This product is similar to other calcium antagonists, there are few reports of adverse reactions of myocardial infarction and chest pain, and these adverse reactions can not be clearly distinguished from the patient's own underlying disease; no abnormal laboratory parameters related to this product have been found.
[Contraindications] Patients allergic to dihydropyridine calcium antagonists are contraindicated.
[Precautions]
L. Patients with impaired liver function: As with all other calcium blockers, the half-life of this product is prolonged when liver function is impaired, but the corresponding recommended dose has not yet been determined. Therefore, this product should be used with great care in this case.
2. Patients with renal failure: This product is widely metabolized into inactive metabolites, and only 10% of the drugs are excreted in the original form through urine. Therefore, the change of blood drug concentration is not related to the degree of renal damage. Patients with renal damage can use normal doses. This product is not dialysis.
3. This product, such as other calcium ion blockers, can rarely have gingival hyperplasia, which mostly occurs during 1-9 months of treatment, but symptoms and hyperplasia can be improved l-21 weeks after drug withdrawal.
4. There is no need to stop the drug before surgery, but the anesthesiologist must know to use this drug for treatment.
. The following conditions are prohibited:
① Severe hypotension:
② Aortic stenosis.
[Use for pregnant and lactating women] The safety of this product for pregnant and lactating women has not been established. In animal experiments, rats were given 10 mg/kg of this product. In addition to delayed delivery and prolonged labor, intrauterine death increased 5 times and the number of littermates decreased by 50%. Therefore, this product can only be used when there is no other safer alternative drug and the disease itself is more dangerous to mother and child. There are no reports on whether this product is discharged into milk.
[Children's medication] There is no information on this product for children.
[Elderly Medication] The peak time of blood drug concentration of this product is similar in elderly and young patients. The area under the curve (AUC) of elderly patients is increased, the elimination half-life is prolonged, and the clearance rate is decreased. It has been reported that older patients were as well tolerated as younger patients when receiving similar doses of amlodipine. Therefore, the elderly patients can use the normal dose, but it is advisable to start with a smaller dose, and then gradually increase the appropriate.
[Drug Interactions]
(1) Narcotics: Inhalation of hydrocarbon drugs with this product can cause hypotension.
(2) non-steroidal anti-inflammatory drugs, especially indomethacin: with this product can weaken the hypotensive effect, may be related to the inhibition of prostaglandin synthesis and (or) cause water, sodium retention.
(3) beta blockers: well tolerated with this product, but can cause excessive hypotension, rare cases can increase the possibility of congestive heart failure.
(4) Estrogen: Use with this product can increase fluid retention and increase blood pressure.
(5) Sulfopyrone (sulfinpyrazone): combined with this product can increase the protein binding rate of amlodipine and change the blood drug concentration.
(6) Lithium preparations: When used with this product, it can cause neurotoxicity, such as nausea, vomiting, diarrhea, ataxia, tremor and (or) numbness, and should be used with caution.
(7) Sympathomimetic amines may attenuate the antihypertensive effect of this product.
[Drug Overdose] Existing data suggest that severe overdose can lead to excessive dilatation of peripheral blood vessels, followed by significant and lasting systemic hypotension, bradycardia, rare II or III degree atrioventricular block, and cardiac arrest in a few patients. The former should be given intravenous dopamine, norepinephrine treatment. The latter should be given atropine, isopropyl kidney, calcium chloride treatment, if there are indications should be placed pacemaker.
[Pharmacological Toxicology]
Pharmacological Effects
This product is a calcium ion influx blocker (I. e. calcium channel blocker or calcium ion antagonist), which can selectively inhibit calcium ion from flowing into vascular smooth muscle and myocardial cells across the membrane, especially for vascular smooth muscle. This product directly dilates vascular smooth muscle, dilates peripheral arterioles, reduces peripheral resistance (afterload), and significantly dilates coronary arteries. This product has a negative inotropic effect in vivo, but has no effect on the sinoatrial node and atrioventricular node.
Toxicological Study
Acute Toxicity in Mice: The LD 50 of L-aspartate amlodipine bulk drug administered by gavage is 80.2 mg/kg(95% confidence limit is 71.3-90.2 mg/kg); The LD 50 for intraperitoneal injection is 62.1 mg/kg(95% confidence limit is 55.0-70.1 mg/kg).
Genotoxicity: Mutagenicity test results indicate no drug-related gene or chromosome level mutagenicity.
Reproductive toxicity: General reproductive toxicity test, oral administration of amlodipine 10 mg/kg/day (based on body surface area, about 8 times the maximum recommended human dose of lOmg) to rats has no damage to fertility. Oral administration of 10 mg/kg of amlodipine (about 8 times and 23 times the maximum recommended human dose of 10mg in terms of body surface area, respectively) to pregnant rats and rabbits during organogenesis had no teratogenic effect on embryos. However, oral administration of amlodipine 10 mg/kg 14 days before mating and pregnancy in rats significantly reduced the number of littermates (about 50%), increased intrauterine mortality (about 5 times), and prolonged pregnancy and labor. Adequate and well-controlled trials have not been conducted in pregnant women, so pregnant women should only take this product during pregnancy when their potential benefits are large and potentially dangerous to the fetus.
It is not clear whether this product is excreted in human milk. In view of the lack of information in this regard, it is recommended to stop using it during lactation.
Carcinogenicity: Amlodipine is carcinogenic in rats and mice for two years. Mixed food doses of 0.5,1.25, and 2.5 mg/kg/day are non-carcinogenic. The highest dose (calculated by body surface area, the mouse dose is equivalent to the maximum recommended clinical dose of 10mg, while the rat dose is twice) is close to the maximum tolerance of mice.
[Pharmacokinetics] It is reported in the literature that this product is well absorbed orally and is not affected by food intake. The plasma protein binding rate is about 97.5, the blood drug concentration reaches the peak value 6-12 hours after single administration, the absolute bioavailability is about 64-80%, the apparent distribution volume is about 21L/kg, the final elimination half-life is about 35-50 hours, once a day, after 7-8 days of continuous administration, blood drug concentration reached steady state. This product is widely metabolized by the liver into inactive metabolites, 10% of which are excreted as original drugs and 60% as metabolites through urine.
【Storage】 Shaded, sealed and stored in a dry place..
【Packing】 Aluminum-plastic plate packaging, each small carton containing seven or fourteen pieces.
[Validity] 24 months.
[Implementation Standard] WS-(X-101)-2005Z
[Approval Document No.] Guoyao Zhun Zi H20020487
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax
:
More information
Create a safe environment to meet the G20
The G20 summit will be held in Hangzhou from September 4 to 5. On August 8, the safety committee of the group company will hold a meeting to make arrangements and put forward requirements for the key work of safety and environmental protection from now to the summit. At the meeting, Chen Tianci, director of the safety management office of the group company, conveyed the requirements of the provincial, municipal and district governments during the G20 summit. Combined with the specific situation and work characteristics of each enterprise, he put forward requirements for environmental protection, safety, public security and other work. In terms of environmental protection management, we must strictly implement the company's environmental protection system, focusing on the management and disposal of solid waste, and the emission control of sewage and dust; at present, in the high temperature season, we must focus on strengthening fire safety management, especially warehousing and hazardous chemical business units., We must strictly do a good job in daily safety inspections; all enterprises must promptly convey the relevant spirit of their superiors to each employee, strengthen ideological and political work, and create a good and harmonious corporate atmosphere. Xiang Chongping, deputy general manager of the group company, supplemented the territorial management of related matters of various enterprises, properly handling internal contradictions, and strengthening network security management. Yu Jianhong, general manager of the group company, stressed at the meeting that safety and environmental protection work should be talked about and grasped every day, and should not be relaxed at any time. Safety accidents seem to be accidental, but in fact they are inevitable, and their roots lie in the usual violations and carelessness. Therefore, all enterprises should seriously organize their employees to carry out self-examination and self-correction, effectively improve their safety awareness, and find out and rectify the small problems and hidden dangers that have been ignored in their work in the past. At the same time, it is necessary to do a good job in the safety zone of operation and the protection of related facilities, through advanced control systems, safe facilities and equipment, standardized
2020
07-31
Create a safe environment to meet the G20
The G20 summit will be held in Hangzhou from September 4 to 5. On August 8, the safety committee of the group company will hold a meeting to make arrangements and put forward requirements for the key work of safety and environmental protection from now to the summit. At the meeting, Chen Tianci, director of the safety management office of the group company, conveyed the requirements of the provincial, municipal and district governments during the G20 summit. Combined with the specific situation and work characteristics of each enterprise, he put forward requirements for environmental protection, safety, public security and other work. In terms of environmental protection management, we must strictly implement the company's environmental protection system, focusing on the management and disposal of solid waste, and the emission control of sewage and dust; at present, in the high temperature season, we must focus on strengthening fire safety management, especially warehousing and hazardous chemical business units., We must strictly do a good job in daily safety inspections; all enterprises must promptly convey the relevant spirit of their superiors to each employee, strengthen ideological and political work, and create a good and harmonious corporate atmosphere. Xiang Chongping, deputy general manager of the group company, supplemented the territorial management of related matters of various enterprises, properly handling internal contradictions, and strengthening network security management. Yu Jianhong, general manager of the group company, stressed at the meeting that safety and environmental protection work should be talked about and grasped every day, and should not be relaxed at any time. Safety accidents seem to be accidental, but in fact they are inevitable, and their roots lie in the usual violations and carelessness. Therefore, all enterprises should seriously organize their employees to carry out self-examination and self-correction, effectively improve their safety awareness, and find out and rectify the small problems and hidden dangers that have been ignored in their work in the past. At the same time, it is necessary to do a good job in the safety zone of operation and the protection of related facilities, through advanced control systems, safe facilities and equipment, standardized
2020
07-30
Technological Innovation Brings Enterprises to the International Stage
Editor's note: As a 17-year-old senior enterprise in the extract industry, Tianjin Jianfeng Natural Products Research and Development Company has devoted more time, energy and funds to R & D and innovation while doing a good job in business operations. It has always been an important direction for them to achieve self breakthrough by turning waste into treasure and technological innovation. Therefore, it has achieved the improvement of market popularity at home and abroad and the rapid growth of sales volume, and has become a key science and technology enterprise in Tianjin Binhai New Area. On July 9, the "Bohai Morning Post" "TEDA Technology Little Giant Tour" column published an exclusive interview, describing the growth experience and a series of achievements of Tianjin Jianfeng Natural Products Company. This article will be reproduced in this newspaper for readers. "Little grape seed" grows into a little giant of science and technology to solve the problem of pesticide residues in plant extracts. Technological innovation has enabled the enterprise to step onto the international stage based on independent innovation and development. Starting from the initial grape seed extraction process, it has gradually grown into the largest professional fruit extract manufacturer in China with dozens of plant extract products conforming to international strict standards and an annual productivity of 2000 tons, tianjin Jianfeng Natural Products Research and Development Co., Ltd. (hereinafter referred to as "Tianjin Jianfeng") has gone through a decade of rapid development. As a supplier of raw materials in health food, beverages, cosmetics, baked goods and many other fields, the concept of "truth and safety" advocated by Tianjin Jianfeng has run through all aspects of R & D and production. Its products are not only well-known in China, but also exported to Europe and the United States. Become a new business card of TEDA. Technological innovation is in line with international standards. "In people's lives, the beverages they drink, the health foods they eat, and the cosmetics they use will contain plant extracts.
2020
07-31
Create a safe environment to meet the G20
The G20 summit will be held in Hangzhou from September 4 to 5. On August 8, the safety committee of the group company will hold a meeting to make arrangements and put forward requirements for the key work of safety and environmental protection from now to the summit. At the meeting, Chen Tianci, director of the safety management office of the group company, conveyed the requirements of the provincial, municipal and district governments during the G20 summit. Combined with the specific situation and work characteristics of each enterprise, he put forward requirements for environmental protection, safety, public security and other work. In terms of environmental protection management, we must strictly implement the company's environmental protection system, focusing on the management and disposal of solid waste, and the emission control of sewage and dust; at present, in the high temperature season, we must focus on strengthening fire safety management, especially warehousing and hazardous chemical business units., We must strictly do a good job in daily safety inspections; all enterprises must promptly convey the relevant spirit of their superiors to each employee, strengthen ideological and political work, and create a good and harmonious corporate atmosphere. Xiang Chongping, deputy general manager of the group company, supplemented the territorial management of related matters of various enterprises, properly handling internal contradictions, and strengthening network security management. Yu Jianhong, general manager of the group company, stressed at the meeting that safety and environmental protection work should be talked about and grasped every day, and should not be relaxed at any time. Safety accidents seem to be accidental, but in fact they are inevitable, and their roots lie in the usual violations and carelessness. Therefore, all enterprises should seriously organize their employees to carry out self-examination and self-correction, effectively improve their safety awareness, and find out and rectify the small problems and hidden dangers that have been ignored in their work in the past. At the same time, it is necessary to do a good job in the safety zone of operation and the protection of related facilities, through advanced control systems, safe facilities and equipment, standardized
2020
07-31
The company requires each business segment to formulate medium-and long-term business plans.
According to our newspaper, "if an enterprise wants to develop in the long run, first of all, managers should have a long-term vision." On July 24, when general manager Yu Jianhong deployed the work for the second half of the year at the semi-annual meeting of the group company, he specifically asked all enterprises to formulate specific medium-and long-term business development plans for the next three to five years according to the industrial development trend and the group development strategy. Before making arrangements for the specific key work in the second half of the year, Yu Jianhong emphatically put forward the requirements for each business sector to formulate a business strategy plan for 2016-2018 according to the industry development trend and the group's development strategy. Yu Jianhong pointed out that the current group company's strategic decision-making and strategic development capabilities and efficiency still need to be improved. The publicity, understanding and implementation of the group's development strategy by various companies are not in place. The lack of medium and long-term business planning in each business sector restricts the business of the company. Development, cultivation of core products and profitability, construction of product brands, improvement of business scale and comprehensive strength. Last year, the group company asked the international trading company to formulate three-year work objectives and sign a three-year economic responsibility system with the company's management team. The actual effect shows that this has made the management team's management ideas clearer and more scientific and rational in terms of target setting, work arrangement and business development. For this reason, the group company put forward the requirements for the formulation of medium and long-term development plans for each business sector at this meeting. According to the industry characteristics of each business segment, market environment and other specific circumstances, the company makes requirements for the key content of the development plan of each business segment. For example, the pharmaceutical sector focuses on sales growth targets for key profitable products, product development and
2020
07-31
The company requires each business segment to formulate medium-and long-term business plans.
According to our newspaper, "if an enterprise wants to develop in the long run, first of all, managers should have a long-term vision." On July 24, when general manager Yu Jianhong deployed the work for the second half of the year at the semi-annual meeting of the group company, he specifically asked all enterprises to formulate specific medium-and long-term business development plans for the next three to five years according to the industrial development trend and the group development strategy. Before making arrangements for the specific key work in the second half of the year, Yu Jianhong emphatically put forward the requirements for each business sector to formulate a business strategy plan for 2016-2018 according to the industry development trend and the group's development strategy. Yu Jianhong pointed out that the current group company's strategic decision-making and strategic development capabilities and efficiency still need to be improved. The publicity, understanding and implementation of the group's development strategy by various companies are not in place. The lack of medium and long-term business planning in each business sector restricts the business of the company. Development, cultivation of core products and profitability, construction of product brands, improvement of business scale and comprehensive strength. Last year, the group company asked the international trading company to formulate three-year work objectives and sign a three-year economic responsibility system with the company's management team. The actual effect shows that this has made the management team's management ideas clearer and more scientific and rational in terms of target setting, work arrangement and business development. For this reason, the group company put forward the requirements for the formulation of medium and long-term development plans for each business sector at this meeting. According to the industry characteristics of each business segment, market environment and other specific circumstances, the company makes requirements for the key content of the development plan of each business segment. For example, the pharmaceutical sector focuses on sales growth targets for key profitable products, product development and
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page